Table 2. Results of univariate COX analysis of LPFS and OS for EGFR-mutant lung adenocarcinama patients with BM.
| patient NO. (%) | Median PFS (mo) | P-value | MedianOS (mo) | P-value | |
|---|---|---|---|---|---|
| group | |||||
| TKI + RT | 67 (50) | 16 | 22 | ||
| TKI | 66 (50) | 11.5 | 0.017 | 15 | 0.015 |
| EGFR Mutation Type | |||||
| exon 21 mutation | 71 (53) | 12 | 16 | ||
| exon 19 deletion | 62 (47) | 16 | 0.239 | 19 | 0.324 |
| Gender | |||||
| male | 61 (46) | 15 | 18 | ||
| female | 72 (54) | 14 | 0.913 | 18.5 | 0.687 |
| KPS | |||||
| < 70 | 11 (8) | 11 | 12 | ||
| ≥ 70 | 122 (92) | 14.5 | 0.451 | 18.5 | 0.032 |
| Extracranial Metastases | |||||
| no | 46 (35) | 15 | 19 | ||
| yes | 87 (65) | 12 | 0.558 | 18 | 0.046 |
| NO. Of Brain Metastases | |||||
| 1 to 3 | 41 (31) | 15 | 19 | ||
| > 3 | 92 (69) | 12 | 0.286 | 18 | 0.454 |
| Age | |||||
| ≤ 65 | 105 (79) | 14 | 18 | ||
| > 65 | 28 (21) | 13 | 0.492 | 17 | 0.72 |
Abbreviations: TKI + RT, tyrosine kinase inhibitors combined with radiation therapy; KPS, karnofsky performance score; LPFS, local progression free survival; OS, overall survival; NSCLC, Non Small Cell Lung Cancer.